Jubilant Life Sciences is currently trading at Rs. 672.50, up by 4.60 points or 0.69% from its previous closing of Rs. 667.90 on the BSE.
The scrip opened at Rs. 668.00 and has touched a high and low of Rs. 676.90 and Rs. 658.35 respectively. So far 16282 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 705.05 on 01-Nov-2016 and a 52 week low of Rs. 272.50 on 20-Jan-2016.
Last one week high and low of the scrip stood at Rs. 676.90 and Rs. 602.00 respectively. The current market cap of the company is Rs. 10702.10 crore.
The promoters holding in the company stood at 54.02%, while institutions and non-institutions held 26.26% and 19.72% respectively.
Jubilant Life Sciences is seeking shareholders’ approval through postal ballot/e-voting to raise up to Rs 1,000 crore through issuance of non-convertible debentures (NCDs) on private placement basis. Approval to the board to raise the amount also stipulates that this could be done in one or more series/tranches during a period of one year from the date of passing the resolution.
Jubilant Life Sciences is an integrated global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: